The effect of calcium channel blockers against scopolamine induced cognitive impairment and oxidative stress
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20163262Keywords:
CCBS, Learning and memory, Scopolamine, Amnesia, Elevated plus maze, Novel object recognition testAbstract
Background: the present work has been planned to find out the effect of calcium channel blockers on learning and memory. there are numerous reports indicating that calcium channel blockers (CCBS) impair memory and learning and on the other side there are reports indicating that CCBS improve memory and learning .This contradictory reports led us to investigate the effect of CCBS on memory and learning by taking three different types of calcium channel blockers verapamil, nimodipine and diltiazem.
Methods: The methods used were elevated plus maze and novel recognition object tests. Ten groups of animals were treated with CCBS and scopolamine. Both prophylactic and curative studies were carried out.
Results: It was evident from our studies that the CCBS effectively antagonized the scopolamine induced cognitive impairment in the paradiagms studied. The inflex ratio and novel object discrimination index also increased indicating decrease in the trancefer latencies. CCBS showed good protection against scopolamine induced cognitive.
Conclusions: In our Studies we observed that verapamil was good in prophylactic studies and diltiazem in curative studies.
References
Striggow F, Ehrlich BE. Ligand-gated calcium channels inside and out. Curr Opin Cell Biol. 1996;8(4):490-5.
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184-5.
Abernethy DR, Schwartz JB. Ca2+-antagonist drugs. N Engl J Med. 1999;341:1447-57.
Betkowski AS, Hauptman PJ. Update on recent clinical trials in congestive heart failure. Curr Opin Cardiol. 2000;15:293-303.
Cutler JA. Ca2+-channel blockers for hypertension--uncertainty continues. N Engl J Med. 1998;338:679-81.
American Heart Association. 1999 heart and stroke statical update. Dallas, Texes: American Heart Asssociation; 2000.
Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51.
Fritze J, Walden J. Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J Neural Transm Suppl. 1995;46:439-53.
Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry. 1990;27:1133-42.
Lopez-Arrieta BJ. Nimodipine for primary degenerative, mixed and vascular dementia, Cochrane Database of Systematic Reviews. 2002:Article no CD000147.
Morich F, Bieber F, Lewis JM, Kaiser L, Cutler NR, Escobar JI, et al. Nimodipine in the treatment of probably Alzheimer's disease results of two multicentre trials. Clin Drug Invest. 1996;11:185-96.
Facchinetti F, Fasolato C, Del Giudice E, Burgo A, Furegato S, Fusco M, et al. Leon, Nimodipine selectively stimulates beta-amyloid1- 42 secretion by a mechanism independent of calcium influx blockage, Neurobiol Aging. 2006;27(2):218-27.
Solomon, Budson AE, Memory PR. Loss: a practical guide for clinicians. Elsevier Saunders. 2011;ISBN9781416035978.
DMS-IV. 4th edition, published by the American Psychiatric Association, Washington D.C.; 1994:142.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC, American Psychiatric Association; 1994.
What is vascular dementia? Alzheimer's Society. Available at http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=161.
Lee AY. Vascular dementia. Chonnam Med J. 2011;47(2):66-71.
Kuller LH. Hormone replacement therapy and its relationship to dementia. J Am Geriatr Soc. 1996;44:878-80.
Geddes, John, Gelder, Michael G.; Mayou, Richard. Psychiatry. Oxford [Oxfordshire]: Oxford University Press; 2005:141:ISBN0-19-852863-9.
Calleo J, Stanley M. Anxiety disorders in later life differentiated diagnosis and treatment strategies. Psychiatric Times. 2008;25(8).
Shin RW. Interaction of aluminum with paired helical tau is involved in neurofibrillary pathology of Alzheimer’s disease. Gerontology. 1997;43 Suppl 1:1623.
Rösler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer’s dementia: Currently available therapeutic strategies. J Neural Transm Suppl. 1998;54:2119.
Kastenholz B. Phytopharmaceuticals in the therapy of younger Alzheimer patients. Webmed Central Biochemistry. 2011;2(3).
Alzheimer’s Association: 1.800.272.3900 Available at www.alz.org. Accessed on 20 July 2011.
Shub, Denis; Kunik, Mark E. Psychiatric comorbidity in persons with dementia: assessment and treatment strategies. Psychiatric Times. 2009;26(4).
Neuropathology group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357(9251):169-75.
Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol. 2003;106(4):374-82.
White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci. 2002;977(9):9-23.
Fujishiro H, Ferman TJ, Boeve BF, Smith GE, Graff-Radford NR, Uitti RJ, et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol. 2008;67(7):649-56.
Brayne REC, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615-21.
McKee A, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy following repetitive head injury. J Neuropathol Exp Neurol. 2009;68(7):709-35.
Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology, 2006;67(9):1605-11.
Lamont P. Cognitive decline in a young adult with pre-existent developmental delay – what the adult neurologist needs to know. Practical Neurology. 2004;4(2):70-87.
Meade, Catherine E. Diagnosing dementia: mental status testing and beyond. Australian Prescriber. 2005;(28):11-3.
Langbehn, Douglas R. Predictors of diagnosis in Huntington disease. Neurology. 2007;68:1710-7.
Rosser, Anne, Hodges JR. Initial letter and semantic category fluency in Alzheimer’s disease, Huntington’s disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry. 1994;57:1389-94.
Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, et al. Profile of cognitive progression in early Huntington’s disease. Neurology. 2003;61:1702-6.
Kirkwood SC, Siemers E, Hodes ME, Conneally PM, Christian JC, Foroud T. Subtle changes among presymptomatic carriers of the Huntington’s disease gene. J Neurol Neurosurg Psychiatry. 2000;69:773-9.
Lawrence A, Hodges J, Rosser A, Kershaw A, French-Constant C, Rubinsztein D, et al. Evidence for specific cognitive deficits in preclinical Huntington’s disease. Brain Pathol. 1998;121:1329-41.
Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation - a longitudinal follow-up study. J Neurol. 2004;251:935-42.
Savla, Nayak G, Palmer BW. Neuropsychology in Alzheimer’s disease and other dementia research. Current Opinions in Psychiatry. 2005(18):621-7.
Cummings JL. Alzheimer's disease. New Engl J Med. 2004;351:56-67.
Koreyzn AD, Vakhapora V. The preparation of the dememtia epidemic. J Neurol Sci. 2007;257:2-4.
Ferreira A, Proenca C, Serralheiro M, Araujo M. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. J Ethnopharmacol. 2006;108:31-7.
Fukuyama R, Mizuno T, Mizuno T, Mori S. Nakajima K, Fushiki S, et al. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients. European Neurology. 2000;43(3):155-60.
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184-5.
Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Aβ peptide. Neuropathol Appl Neurobiol. 1999;25:81-97.
Wilson CA, Doms RW, Lee VMY. Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:787-94.
Rubinsztein DC. The genetics of Alzheimer's disease. Prog Neurobiol. 1997;52:447-54.
Goate A, Chartier-Harlin MC, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-6.
Kamino K, Orr HT, Payami H. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992;51:998-1014.
Clark RF, Goate AM. Molecular genetics of Alzheimer's disease. Arch Neurol. 1993;50:1164-72.
Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, et al. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 1992;9:129-37.
Shea TB, Beermann ML, Honda T, Nixon RA. Secretion of amyloid precursor protein and laminin by cultured astrocytes is influenced by culture conditions. J Neurosci Res. 1994;37:197-207.
Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid β-protein fibrillogenesis structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274:25945-52.
Lazo ND, Downing DT. Amyloid fibrils may be assembled from α-helical protofibrils. Biochemistry. 1998;37:1731-5.
Bandiera T, Lansen J, Post C, Varasi M. Inhibitors of Aβpeptide aggregation as potential anti-Alzheimer agents. Curr Med Chem. 1997;4:159-70.
Maruyama K, Terakado K, Usami M, Yoshikawa K. Formation of amyloid- like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor. Nature. 1990;347:566-9.
Yamaguchi H, Yamazaki T, Ishiguro K. Ultrastructural localization of Alzheimer amyloid β/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta Neuropathol (Berl). 1992;85:15-22.
Ferreira A, Caceres A, Kosik KS. Intraneuronal compartments of the amyloid precursor protein. J Neurosci. 1993;13:3112-23.
Mann DM, Brown A, Prinja D, Davies CA, Landon M, Masters CL. An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol Appl Neurobiol. 1989;15:317-29.
Gandy S, Greengard P. Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. Biochimie. 1994;76:300-3.
Gabuzda D, Busciglio J, Yankner BA. Inhibition of β-amyloid production by activation of protein kinase C. J Neurochem. 1993;61:2326-9.
Nitsch RM, Slack BE, Farber SA. Receptor-coupled amyloid precursor protein processing. Ann N Y Acad Sci. 1993;695:122-7.
Govoni S, Racchi M, Bergamaschi S. Defective protein kinase C_ leads to impaired secretion of soluble β-amyloid precursor protein from Alzheimer's disease fibroblasts. Ann NY Acad Sci. 1996;777:332-7.
Benussi L, Govoni S, Gasparini L. Specific role for protein kinase C in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblast. Neurosci Lett. 1998;240:97-101.
LeBlanc AC, Koutroumanis M, Goodyer CG. Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Aβ production in human primary neuron cultures. J Neurosci. 1998;18:2907-13.
Nitsch RM, Deng MH, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2e receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 1996;271:4188-94.
Vassar R, Bennett BD, Babu-Khan S. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735-41.
Selkoe DJ, Yamazaki T, Citron M. The role of APP processing and trafficking pathways in the formation of amyloid β-protein. Ann NY Acad Sci. 1996;777:57-64.
Suzuki N, Cheung TT, Cai XD. An increased percentage of long amyloid b protein secreted by familial amyloid Aβprotein precursor (βAPP717) mutants. Science. 1994;264:1336-40.
Tamaoka A, Odaka A, Ishibashi Y. APP717 missense mutation affects the ratio of amyloid Aβprotein species (Aβ1-42/43 and Aβ1-40) in familial Alzheimer's disease brain. J Biol Chem. 1994;269:32721-4.
Citron M, Vigo-Pelfrey C, Teplow DB. Excessive production of amyloid -protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA. 1994;91:11993-7.
Kosaka T, Imagawa M, Seki K. The αAPP717 Alzheimer mutation increases the percentage of plasma amyloid-Aβprotein ending at Aβ42(43). Neurology. 1997;48:741-5.
Cras P, van Harskamp F, Hendriks L. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala Gly mutation. Acta Neuropathol (Berl). 1998;96:253-60.
